Coherus Biosciences

Coherus Biosciences is a biopharmaceutical company that engages in the development, manufacture, and commercialization of biologic therapeutics. The company develops biologic medicines primarily for the treatment of oncology and inflammatory diseases. It focuses on process science, analytical characterization, protein production, and clinical-regulatory development. Its pipeline includes Immunology, anti-tumor necrosis factor (Anti-TNF) biosimilar candidates; Ophthalmology biosimilar candidates; and Oncology Biosimilar candidates.

Coherus Biosciences headquartered in United States, North America, operates in the Biotechnology, Health Care, Medical, Therapeutics, Oncology sector. The company focuses on Biotechnology and has secured $404.7B in funding across 320 round(s). With a team of 251-500 employees, Coherus Biosciences is actively contributing to advancements in Biotechnology. Their latest funding round, Series B - Coherus Biosciences, raised $61.5M. Discover more about their projects, partnerships, and impact on our platform.